Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

Grants

Funding Acknowledgements

I, Professor SM Garland, have received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, I have received funding through my institution to conduct HPV vaccine studies for MSD and GSK. I am a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV.